Nxera Pharma Co., Ltd. (SOLTF)
OTCMKTS · Delayed Price · Currency is USD
6.25
0.00 (0.00%)
Aug 26, 2025, 8:00 PM EDT
Nxera Pharma Employees
Nxera Pharma had 374 employees as of December 31, 2024. The number of employees increased by 24 or 6.86% compared to the previous year.
Employees
374
Change (1Y)
24
Growth (1Y)
6.86%
Revenue / Employee
$556,079
Profits / Employee
-$58,300
Market Cap
556.43M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 374 | 24 | 6.86% |
Dec 31, 2023 | 350 | 148 | 73.27% |
Dec 31, 2022 | 202 | 4 | 2.02% |
Dec 31, 2021 | 198 | 8 | 4.21% |
Dec 31, 2020 | 190 | 27 | 16.56% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
Elite Pharmaceuticals | 68 |
Tian'an Technology Group | 8 |
Glass House Brands | 374 |
CytoDyn | 13 |
Northwest Biotherapeutics | 25 |
American Oncology Network | 1,914 |
Silence Therapeutics | 116 |
Longduoduo Company | 49 |
Nxera Pharma News
- 20 days ago - Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025 - GlobeNewsWire
- 23 days ago - Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management - GlobeNewsWire
- 7 weeks ago - Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessa's Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist - GlobeNewsWire
- 3 months ago - Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568 - GlobeNewsWire
- 3 months ago - Nxera Pharma Achieves Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases - GlobeNewsWire
- 3 months ago - Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 - GlobeNewsWire
- 4 months ago - Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2025 - GlobeNewsWire
- 4 months ago - Nxera Pharma's Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia - GlobeNewsWire